Literature DB >> 26006718

Eosinophilic Drug Allergy.

Merin Kuruvilla1, David A Khan2.   

Abstract

While peripheral or tissue eosinophilia may certainly characterize drug eruptions, this feature is hardly pathognomonic for a medication-induced etiology. While delayed drug hypersensitivity reactions with prominent eosinophilic recruitment have been typically classified as type IVb reactions, their pathophysiology is now known to be more complex. Eosinophilic drug reactions have a diversity of presentations and may be benign and self-limited to severe and life-threatening. The extent of clinical involvement is also heterogeneous, ranging from isolated peripheral eosinophilia or single organ involvement (most often the skin and lung) to systemic disease affecting multiple organs, classically exemplified by drug-reaction with eosinophilia and systemic symptoms (DRESS). The spectrum of implicated medications in the causation of DRESS is ever expanding, and multiple factors including drug metabolites, specific HLA alleles, herpes viruses, and immune system activation have been implicated in pathogenesis. Due to this complex interplay of various factors, diagnostic workup in terms of skin and laboratory testing has not been validated. Similarly, the lack of controlled trials limits treatment options. This review also describes other localized as well as systemic manifestations of eosinophilic disease induced by various medication classes, including their individual pathophysiology, diagnosis, and management. Given the multitude of clinical patterns associated with eosinophilic drug allergy, the diagnosis can be challenging. Considerable deficits in our knowledge of these presentations remain, but the potential for severe reactions should be borne in mind in order to facilitate diagnosis and institute appropriate management.

Entities:  

Keywords:  Aspirin-exacerbated respiratory disease; Drug allergy; Drug exanthema; Drug-reaction with eosinophilia and systemic symptoms (DRESS); Eosinophilia; Eosinophilic pneumonia

Mesh:

Year:  2016        PMID: 26006718     DOI: 10.1007/s12016-015-8491-x

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   10.817


  115 in total

Review 1.  The changing profile of acute tubulointerstitial nephritis.

Authors:  Richard J Baker; Charles D Pusey
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

Review 2.  Eosinophilic pustular folliculitis induced by carbamazepine.

Authors:  S Mizoguchi; M Setoyama; Y Higashi; H Hozumi; T Kanzaki
Journal:  J Am Acad Dermatol       Date:  1998-04       Impact factor: 11.527

3.  Purtscher-like retinopathy related to drug-induced hypersensitivity syndrome.

Authors:  Muge Coban-Karatas; Tuba Turunc; Rana Altan-Yaycioglu
Journal:  Ocul Immunol Inflamm       Date:  2012-11-19       Impact factor: 3.070

4.  Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.

Authors:  Alvaro C Laga; Ruth A Vleugels; Abrar A Qureshi; Elsa F Velazquez
Journal:  Am J Dermatopathol       Date:  2010-08       Impact factor: 1.533

5.  DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to Vancomycin.

Authors:  Paloma O'Meara; Rozita Borici-Mazi; A Ross Morton; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2011-10-03       Impact factor: 3.406

6.  Dapsone induced eosinophilic pneumonia.

Authors:  T Adar; O Tayer-Shifman; M Mizrahi; S Tavdi; O Barak; M Shalit
Journal:  Eur Ann Allergy Clin Immunol       Date:  2012-06

7.  The eosinophilic fasciitis syndrome after phenytoin (dilantin) therapy.

Authors:  R R Buchanan; D A Gordon; T J Muckle; F McKenna; G Kraag
Journal:  J Rheumatol       Date:  1980 Sep-Oct       Impact factor: 4.666

8.  Eosinophilic rash secondary to temsirolimus.

Authors:  Mona Gandhi; Timothy Kuzel; Mario Lacouture
Journal:  Clin Genitourin Cancer       Date:  2009-08       Impact factor: 2.872

9.  Nitrofurantoin: cause of DRESS syndrome.

Authors:  Rodrigo Nazário Leão; Paulo Barreto; Ricardo R Leão; José Vaz Ribeiro
Journal:  BMJ Case Rep       Date:  2013-05-08

10.  Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spironolactone: DRESS syndrome.

Authors:  Pierre-Dominique Ghislain; Anne-Dominique Bodarwe; Olivier Vanderdonckt; Dominique Tennstedt; Liliane Marot; Jean-Marie Lachapelle
Journal:  Acta Derm Venereol       Date:  2004       Impact factor: 4.437

View more
  7 in total

1.  Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.

Authors:  Eo Jin Kim; Min-Hee Ryu; Sook Ryun Park; Mo Youl Beck; Woo Jin Lee; Mi Woo Lee; Yoon-Koo Kang
Journal:  Oncologist       Date:  2020-07-12

2.  Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.

Authors:  Sirinoot Palapinyo; Jettanong Klaewsongkram; Virote Sriuranpong; Nutthada Areepium
Journal:  Pharm Pract (Granada)       Date:  2022-03-31

Review 3.  Approach to Patients with Eosinophilia.

Authors:  Fei Li Kuang
Journal:  Med Clin North Am       Date:  2020-01       Impact factor: 5.456

Review 4.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.834

5.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.530

Review 6.  Eosinophils from Physiology to Disease: A Comprehensive Review.

Authors:  Giuseppe A Ramirez; Mona-Rita Yacoub; Marco Ripa; Daniele Mannina; Adriana Cariddi; Nicoletta Saporiti; Fabio Ciceri; Antonella Castagna; Giselda Colombo; Lorenzo Dagna
Journal:  Biomed Res Int       Date:  2018-01-28       Impact factor: 3.411

Review 7.  Current Perspectives on Severe Drug Eruption.

Authors:  Jingzhan Zhang; Zixian Lei; Chen Xu; Juan Zhao; Xiaojing Kang
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-17       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.